Negative regulation of the type i interferon signaling pathway by synthetic toll-like receptor 7 ligands

Journal of Interferon and Cytokine Research

Volumn 32, Issue 6, 2012, Pages 254-268

  Forsbach, Alexandra ^a   Müller, Christian ^a   Montino, Carmen ^a   Kritzler, Andrea ^a   Nguyen, Toan ^b   Weeratna, Risini ^a   Jurk, Marion ^a   Vollmer, Jörg ^a  

^a PFIZER INC   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; LIGAND; LOXORIBINE; NUCLEIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ARTICLE; BINDING COMPETITION; BINDING SITE; CELL ACTIVATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; DOWN-REGULATION; HUMANS; INTERFERON TYPE I; LIGANDS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT2 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 7;

EID: 84862159395     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0091     Document Type: Article

References (100)

1. Abel K, Wang Y, Fritts L, et al. 2005. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol 12:606-621. (Pubitemid 41184721)
2. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, and Wagner H. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958-1968. (Pubitemid 34814552)
3. Akira S and Hemmi H. 2003. Recognition of pathogenassociated molecular patterns by TLR family. Immunol Lett 85:85-95. (Pubitemid 36071561)
4. Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA. 2001. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 413:732-738. (Pubitemid 33009951)
5. Bauer S, Kirschning CJ, Hacker H, et al. 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98:9237-9242. (Pubitemid 32743900)
6. Bell JK, Botos I, Hall PR, et al. 2005. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A 102:10976-10980. (Pubitemid 41105978)
7. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, and Segal DM. 2003. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 24:528-533. (Pubitemid 37205203)
8. Berghofer B, Haley G, Frommer T, Bein G, and Hackstein H. 2007. Natural and synthetic TLR7 ligands inhibit CpG-A-And CpG-C-oligodeoxynucleotide-induced IFN-Alpha production. J Immunol 178:4072-4079. (Pubitemid 46492355)
9. Berkeredjian-Ding IB, Wagner M, Hornung V, et al. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 174:4043-4050. (Pubitemid 40395980)
10. Beutler B and Rehli M. 2002. Evolution of the TIR, tolls and TLRs: functional inferences from computational biology. Curr Top Microbiol Immunol 270:1-21. (Pubitemid 35448150)
11. Bluyssen AR, Durbin JE, and Levy DE. 1996. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev 7:11-17. (Pubitemid 27205175)
12. Bluyssen HA and Levy DE. 1997. Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J Biol Chem 272:4600-4605. (Pubitemid 27078542)
13. Borges S, Moudilou E, Vouyovitch C, et al. 2008. Involvement of a JAK/STAT pathway inhibitor: cytokine inducible SH2 containing protein in breast cancer. Adv Exp Med Biol 617:321-329.
14. Brassard DL, Grace MJ, and Bordens RW. 2002. Interferon-Alpha as an immunotherapeutic protein. J Leukoc Biol 71:565-581.
15. Choi MK, Wang Z, Ban T, et al. 2009. A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA. Proc Natl Acad Sci U S A 106:17870-17875.
16. Chuang TH and Ulevitch RJ. 2000. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11:372-378. (Pubitemid 32268894)
17. Coffey AJ, Brooksbank RA, Brandau O, et al. 1998. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20:129-135. (Pubitemid 28455444)
18. Dai J, Megjugorac NJ, Amrute SB, and Fitzgerald-Bocarsly P. 2004. Regulation of IFN regulatory factor-7 and IFN-Alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J Immunol 173:1535-1548. (Pubitemid 38971583)
19. Darnell JE Jr., Kerr IM, and Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421. (Pubitemid 24217131)
20. Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, and La Monica N. 2009. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 16:462-472.
21. Diebold SS, Kaisho T, Hemmi H, Akira S, and Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531. (Pubitemid 38314425)
22. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, and Sousa CR. 2006. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 36:3256-3267. (Pubitemid 44932727)
23. Dunn GP, Bruce AT, Sheehan KC, et al. 2005. A critical function for type I interferons in cancer immunoediting. Nat Immunol 6:722-729. (Pubitemid 41716746)
24. Elco CP and Sen GC. 2007. Stat1 required for interferoninducible but not constitutive responsiveness to extracellular dsRNA. J Interferon Cytokine Res 27:411-424.
25. Faul EJ, Wanjalla CN, Suthar MS, Gale M, Wirblich C, and Schnell MJ. 2010. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling. PLoS Pathog 6:e1001016.
26. Fife KH, Meng TC, Ferris DG, and Liu P. 2008. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother 52:477-482. (Pubitemid 351170817)
27. Fletcher S, Page BD, Zhang X, et al. 2011. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem 6:1459-1470.
28. Forsbach A, Nemorin J, Volp K, et al. 2007. Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 17:405-417.
29. Forsbach A, Nemorin JG, Montino C, et al. 2008. Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses. J Immunol 180:3729-3738.
30. Gerhartz C, Heesel B, Sasse J, et al. 1996. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 271:12991-12998.
31. Gitlin L, Barchet W, Gilfillan S, et al. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 103:8459-8464. (Pubitemid 43838477)
32. Gorden KB, Gorski KS, Gibson SJ, et al. 2005. Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8. J Immunol 174:1259-1268.
33. Gorski KS, Waller EL, Bjornton-Severson J, et al. 2006. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115-1126. (Pubitemid 43923429)
34. Gowen BB, Wong MH, Jung KH, et al. 2007. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA, poly(-I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178:5200-5208. (Pubitemid 46595304)
35. Hartmann G, Battiany J, Poeck H, et al. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-A induction in plasmacytoid dendritic cells. Eur J Immunol 33:1633-1641. (Pubitemid 36790424)
36. Hayashi T, Gray CS, Chan M, et al. 2009. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A 106:2764-2769.
37. Heil F, Ahmad-Nejad P, Hemmi H, et al. 2003. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33:2987-2997. (Pubitemid 37428331)
38. Heil F, Hemmi H, Hochrein H, et al. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529. (Pubitemid 38314424)
39. Hemmann U, Gerhartz C, Heesel B, et al. 1996. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem 271:12999-13007.
40. Honda K, Ohba Y, Yanai H, et al. 2005a. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040. (Pubitemid 40586053)
41. Honda K, Yanai H, Negishi H, et al. 2005b. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777. (Pubitemid 44739521)
42. Hornung V, Ellegast J, Kim S, et al. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997.
43. Hornung V, Guenthner-Biller M, Bourquin C, et al. 2005. Sequence-specific potent induction of IFN-Alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270. (Pubitemid 40460553)
44. Hornung V, Rothenfusser S, Britsch S, et al. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537. (Pubitemid 34441357)
45. Ihle JN and Kerr IM. 1995. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11:69-74.
46. Isobe Y, Kurimoto A, Tobe M, et al. 2006. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem 49:2088-2095.
47. Ito T, Amakawa R, Kaisho T, et al. 2002. Interferon-Alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 195:1507-1512. (Pubitemid 34602828)
48. Iwasaki A and Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995. (Pubitemid 41057715)
49. Jurk M, Heil F, Vollmer J, et al. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499. (Pubitemid 34669818)
50. Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, and Uhlmann E. 2006a. Structure-Activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. ChemMedChem 1:1007-1014. (Pubitemid 44448800)
51. Jurk M, Kritzler A, Schulte B, et al. 2006b. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 36:1815-1826. (Pubitemid 44089048)
52. Jurk M, Schulte B, Kritzler A, et al. 2004. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology 209:141-154. (Pubitemid 39255698)
53. Kalali BN, Kollisch G, Mages J, et al. 2008. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling. J Immunol 181:2694-2704.
54. Kato H, Takeuchi O, Sato S, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-105.
55. Kenakin T. 2002. Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1:103-110. (Pubitemid 41646517)
56. Kessler DS, Veals SA, Fu XY, and Levy DE. 1990. Interferonalpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 4:1753-1765.
57. Klinman DM, Yi AK, Beaucage SL, Conover J, and Krieg AM. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci.U S A 93:2879-2883. (Pubitemid 26116242)
58. Kokkinopoulos I, Jordan WJ, and Ritter MA. 2005. Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol Immunol 42:957-968. (Pubitemid 40489021)
59. Kong XF, Zhang XX, Gong QM, et al. 2007. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-Alpha treatment. J Interferon Cytokine Res 27:809-818.
60. Krieg AM 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760. (Pubitemid 34293438)
61. Krieg AM, Yi AK, Matson S, et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
62. Kurimoto A, Ogino T, Ichii S, et al. 2003. Synthesis and structureactivity relationships of 2-Amino-8-hydroxyadenines as orally active interferon inducing agents. Bioorg Med Chem 11:5501-5508. (Pubitemid 37464677)
63. Latz E, Schoenemeyer A, Visintin A, et al. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198. (Pubitemid 38208361)
64. Lee J, Wu CC, Lee KJ, et al. 2006. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 103:1828-1833. (Pubitemid 43228778)
65. Lin L, Deangelis S, Foust E, et al. 2010a. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer 9:217.
66. Lin L, Hutzen B, Li PK, et al. 2010b. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12:39-50.
67. Lund JM, Alexopoulou L, Sato A, et al. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101:5598-5603. (Pubitemid 38481202)
68. Marques JT, Devosse T, Wang D, et al. 2006. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 24:559-565.
69. Marshall JD, Fearon K, Abbate C, et al. 2003. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 73:781-792. (Pubitemid 38040457)
70. Marshall JD, Heeke DS, Gesner ML, Livingston B, and Van Nest G. 2007. Negative regulation of TLR9-mediated IFN-{alpha} induction by a small-molecule, synthetic TLR7 ligand. J Leukoc Biol 82:497-508. (Pubitemid 47367140)
71. Nichols KE, Harkin DP, Levitz S, et al. 1998. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 95:13765-13770. (Pubitemid 28523047)
72. Okumura A, Lu G, Pitha-Rowe I, and Pitha PM. 2006. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A 103:1440-1445. (Pubitemid 43191184)
73. Peng G, Guo Z, Kiniwa Y, et al. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309:1380-1384. (Pubitemid 41209366)
74. Picaud S, Bardot B, De Maeyer E, and Seif I. 2002. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 22:457-462. (Pubitemid 34579548)
75. Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. 1994. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 330:1488-1491. (Pubitemid 24151406)
76. Scarabelli TM, Mariotto S, Abdel-Azeim S, et al. 2009. Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. FEBS Lett 583:531-541.
77. Schlee M, Roth A, Hornung V, et al. 2009. Recognition of 5' triphosphate by RIG-I helicase requires short blunt doublestranded RNA as contained in panhandle of negative-strand virus. Immunity 31:25-34.
78. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, and Meng TC. 2008. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 159: 205-210. (Pubitemid 351874499)
79. Tabeta K, Georgel P, Janssen E, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 101:3516-3521. (Pubitemid 38338227)
80. Takahasi K, Yoneyama M, Nishihori T, et al. 2008. Nonself RNAsensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 29:428-440.
81. Takaoka A, Hayakawa S, Yanai H, et al. 2003. Integration of interferon-Alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516-523. (Pubitemid 36975769)
82. Takaoka A, Yanai H, Kondo S, et al. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243-249. (Pubitemid 40388058)
83. Tamassia N, Le M, V, Rossato M, et al. 2008. Activation of an immunoregulatory and antiviral gene expression program in poly(I:C)-transfected human neutrophils. J Immunol 181: 6563-6573.
84. Tartaglia M, Mehler EL, Goldberg R, et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468. (Pubitemid 34326699)
85. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, and Parkinson T. 2007. investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51:2969-2978. (Pubitemid 47206238)
86. Thyrell L, Erickson S, Zhivotovsky B, et al. 2002. Mechanisms of interferon-Alpha induced apoptosis in malignant cells. Oncogene 21:1251-1262. (Pubitemid 34185242)
87. Tluk S, Jurk M, Forsbach A, et al. 2009. Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. Int Immunol 21:607-619.
88. Tomai MA, Gibson SJ, Imbertson LM, et al. 1995. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 28:253-264.
89. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, and Waldschmidt TJ. 2000. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203:55-65. (Pubitemid 30627030)
90. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, and Vasilakos JP. 2007. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 6:835-847. (Pubitemid 47607857)
91. Vollmer J, Jurk M, Samulowitz U, et al. 2004a. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 10:431-438. (Pubitemid 39618559)
92. Vollmer J, Rankin R, Hartmann H, et al. 2004b. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 48:2314-2317. (Pubitemid 38691640)
93. Vollmer J, Tluk S, Schmitz C, et al. 2005. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202:1575-1585. (Pubitemid 41746603)
94. Vollmer J, Weeratna R, Payette P, et al. 2004c. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251-262. (Pubitemid 38111541)
95. Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, and Tuting T. 2005. Type I interferon-Associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124:37-48. (Pubitemid 40944372)
96. Williams BR. 1991. Transcriptional regulation of interferonstimulated genes. Eur J Biochem 200:1-11.
97. Wu CC, Hayashi T, Takabayashi K, et al. 2007. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A 104:3990-3995. (Pubitemid 47181566)
98. Wu JJ, Huang DB, and Tyring SK. 2004. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 64:79-83. (Pubitemid 39446130)
99. Yoneyama M, Kikuchi M, Natsukawa T, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNAinduced innate antiviral responses. Nat Immunol 5:730-737. (Pubitemid 39023305)
100. Zamanian-Daryoush M, Marques JT, Gantier MP, et al. 2008. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res 28:221-233. (Pubitemid 351591447)